Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors

INTRODUCTION: Eptacog beta is a new recombinant activated human factor VII bypassing agent approved in the United States for the treatment and control of bleeding in patients with haemophilia A or B with inhibitors 12 years of age or older. AIM: To prospectively assess in a phase 3 clinical trial (P...

Descripción completa

Detalles Bibliográficos
Autores principales: Pipe, Steven W., Hermans, Cédric, Chitlur, Meera, Carcao, Manuel, Castaman, Giancarlo, Davis, Joanna A., Ducore, Jonathan, Dunn, Amy L., Escobar, Miguel, Journeycake, Janna, Khan, Osman, Mahlangu, Johnny, Meeks, Shannon L., Mitha, Ismail Haroon, Négrier, Claude, Nowak‐Göttl, Ulrike, Recht, Michael, Chrisentery‐Singleton, Tammuella, Stasyshyn, Oleksandra, Vilchevska, Kateryna V., Martinez, Laura Villarreal, Wang, Michael, Windyga, Jerzy, Young, Guy, Alexander, W. Allan, Bonzo, Daniel, Macie, Christopher, Mitchell, Ian S., Sauty, Evelyne, Wilkinson, Thomas A., Shapiro, Amy D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542908/
https://www.ncbi.nlm.nih.gov/pubmed/35475308
http://dx.doi.org/10.1111/hae.14563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542908/
https://www.ncbi.nlm.nih.gov/pubmed/35475308
http://dx.doi.org/10.1111/hae.14563

Ejemplares similares